ong-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Phase 1
Recruiting
- Conditions
- Sickle-cell diseaseMedDRA version: 21.0Level: PTClassification code: 10040644Term: Sickle cell disease Class: 100000004850Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2024-513901-30-00
- Lead Sponsor
- Bluebird Bio Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/ legal guardian(s), Treated with drug product for therapy of SCD in a bluebird bio-sponsored clinical study
Exclusion Criteria
There are no exclusion criteria for this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method